Pavion Blue Capital LLC Purchases 1,000 Shares of Bristol-Myers Squibb (NYSE:BMY)

Pavion Blue Capital LLC raised its stake in Bristol-Myers Squibb (NYSE:BMY) by 7.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,233 shares of the biopharmaceutical company’s stock after acquiring an additional 1,000 shares during the period. Pavion Blue Capital LLC’s holdings in Bristol-Myers Squibb were worth $862,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Howard Capital Management Inc. grew its position in Bristol-Myers Squibb by 47.4% in the fourth quarter. Howard Capital Management Inc. now owns 19,949 shares of the biopharmaceutical company’s stock valued at $1,128,000 after acquiring an additional 6,416 shares during the period. Wealthspire Advisors LLC grew its position in Bristol-Myers Squibb by 0.6% in the fourth quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company’s stock valued at $1,622,000 after acquiring an additional 170 shares during the period. Kooman & Associates bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at $209,000. TCW Group Inc. grew its position in Bristol-Myers Squibb by 2.0% in the fourth quarter. TCW Group Inc. now owns 37,339 shares of the biopharmaceutical company’s stock valued at $2,112,000 after acquiring an additional 721 shares during the period. Finally, First Horizon Advisors Inc. grew its position in Bristol-Myers Squibb by 2.8% in the fourth quarter. First Horizon Advisors Inc. now owns 406,458 shares of the biopharmaceutical company’s stock valued at $22,989,000 after acquiring an additional 11,072 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction on Friday, February 14th. The stock was bought at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now directly owns 63,932 shares of the company’s stock, valued at $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.09% of the company’s stock.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of analyst reports. Bank of America reiterated a “neutral” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Leerink Partnrs raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Daiwa America raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Morgan Stanley boosted their price objective on Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a research note on Tuesday, November 12th. Finally, Wolfe Research initiated coverage on Bristol-Myers Squibb in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Trading Up 0.1 %

Shares of BMY opened at $55.85 on Friday. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.10. The stock’s fifty day simple moving average is $56.99 and its 200-day simple moving average is $54.35. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The firm has a market capitalization of $113.33 billion, a PE ratio of -12.63, a price-to-earnings-growth ratio of 2.07 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. As a group, research analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were paid a $0.62 dividend. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date was Friday, January 3rd. This represents a $2.48 annualized dividend and a yield of 4.44%. Bristol-Myers Squibb’s dividend payout ratio is presently -56.11%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.